Medicare’s Oversight of Compounded Pharmaceuticals Used in Hospitals.
Levinson DR. Washington, DC: US Department of Health and Human Services, Office of the Inspector General; January 2015. Report No. OEI-01-13-00400.
A widely-reported meningitis outbreak in the United States uncovered quality and safety issues associated with the use of compounded sterile preparations. This publication describes an analysis of five accreditationorganizations and their ability to provide oversight and inspection of Medicare hospitals that contract with compounding entities. The authors offer recommendations to help hospitals determine if their compounded sterile preparations contracts ensure products are prepared safely for use, including targeted training forsurveyors related to compounding and improved contracting processes.
Free full text (PDF)
Related news article
Advances in Patient Safety: From Research to Implementation.
Rockville, MD: Agency for Healthcare Research and Quality; February 2005. AHRQ Publication Nos. 050021 (1-4).
The Food and Drug Administration's National Drug Code Directory.
Office of the Inspector General. Washington, DC: US Department of Health and Human Services; August 2006. Report No. OEI-06-05-00060.
"What Did the Doctor Say?:" Improving Health Literacy to Protect Patient Safety.
Oakbrook Terrace, IL: The Joint Commission; 2007.
COMMENTARYView all related resources...
Developing a medication patient safety program — infrastructure and strategy.
Mark SM, Weber RJ. Hosp Pharm. 2007;42:149-156.
No hay comentarios:
Publicar un comentario